Relenza Studies In High-Risk Populations Might Show More Efficacy - Cmte.
Additional studies of Glaxo Wellcome's Relenza Diskhaler should be targeted to specific high-risk populations in order to more clearly show efficacy of zanamivir against influenza, members of FDA's Antiviral Drugs Advisory Committee said Feb. 24.
You may also be interested in...
A Relenza prophylaxis indication is key to the future growth of the inhaled neuraminidase inhibitor, Glaxo Wellcome Chairman Richard Sykes said July 27 at a half-year results meeting in London.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011